Effects of melanocortin receptor ligands on ethanol intake and opioid peptide levels in alcohol-preferring AA rats.

Ploj K, Roman E, Kask A, Hyytiä P, Schiöth HB, Wikberg JE, Nylander I

Brain research bulletin1 Oct 2002Cited by 44 (Europe PMC)

PMID12379439DOI10.1016/s0361-9230(02)00844-4PepBankPUB-12379439

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In alcohol-preferring AA rats with established ethanol intake, intracerebroventricular MTII reduced ethanol intake.
In plain wordsIn alcohol-preferring rats, MTII given in the brain reduced alcohol drinking.
Peptide
Melanotan II
Outcome
DecreaseEthanol intake
Study
ratn: not reported in source
Alcohol-preferring AA rats
Comparator
Artificial cerebrospinal fluid
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
1 nmol/rat · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
MTII caused a reduction in ethanol intake and ethanol preference
1 context sentence(design, population, supporting numbers)
Summary · context
To further study the involvement of the MCs in drug dependence, we analysed the effects of the MC(4)-receptor antagonist HS014 (1 nmol/rat), and the non-selective MC-receptor agonist MTII (1 nmol/rat), using i.c.v. administration, on ethanol intake in alcohol-preferring AA rats.
Report a problemFND-1237943901
02AnimalAnimal study (in vivo)Efficacy outcome
In alcohol-preferring AA rats with established ethanol intake, intracerebroventricular MTII reduced ethanol preference.
In plain wordsIn alcohol-preferring rats, MTII given in the brain reduced their preference for alcohol.
Peptide
Melanotan II
Outcome
DecreaseEthanol preference
Study
ratn: not reported in source
Alcohol-preferring AA rats
Comparator
Artificial cerebrospinal fluid
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
1 nmol/rat · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
MTII caused a reduction in ethanol intake and ethanol preference
1 context sentence(design, population, supporting numbers)
Summary · context
To further study the involvement of the MCs in drug dependence, we analysed the effects of the MC(4)-receptor antagonist HS014 (1 nmol/rat), and the non-selective MC-receptor agonist MTII (1 nmol/rat), using i.c.v. administration, on ethanol intake in alcohol-preferring AA rats.
Report a problemFND-1237943902
03AnimalAnimal study (in vivo)Efficacy outcome
In alcohol-preferring AA rats, MTII had no effect on water intake.
In plain wordsIn alcohol-preferring rats, MTII did not change water intake.
Peptide
Melanotan II
Outcome
No significant changeWater intake
Study
ratn: not reported in source
Alcohol-preferring AA rats
Comparator
Artificial cerebrospinal fluid
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 nmol/rat · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
No effect on water intake was observed.
1 context sentence(design, population, supporting numbers)
Summary · context
To further study the involvement of the MCs in drug dependence, we analysed the effects of the MC(4)-receptor antagonist HS014 (1 nmol/rat), and the non-selective MC-receptor agonist MTII (1 nmol/rat), using i.c.v. administration, on ethanol intake in alcohol-preferring AA rats.
Report a problemFND-1237943903
04AnimalAnimal study (in vivo)Efficacy outcome
In alcohol-preferring AA rats, MTII decreased food intake.
In plain wordsIn alcohol-preferring rats, MTII reduced food intake.
Peptide
Melanotan II
Outcome
DecreaseFood intake
Study
ratn: not reported in source
Alcohol-preferring AA rats
Comparator
Artificial cerebrospinal fluid
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 nmol/rat · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
A decrease in food intake was detected after MTII
1 context sentence(design, population, supporting numbers)
Summary · context
To further study the involvement of the MCs in drug dependence, we analysed the effects of the MC(4)-receptor antagonist HS014 (1 nmol/rat), and the non-selective MC-receptor agonist MTII (1 nmol/rat), using i.c.v. administration, on ethanol intake in alcohol-preferring AA rats.
Report a problemFND-1237943904
05AnimalAnimal study (in vivo)Mechanism
In alcohol-preferring AA rats with established ethanol intake, MTII altered dynorphin B and Met-enkephalin-Arg(6)Phe(7) immunoreactive levels in several brain areas and the pituitary gland; the abstract does not give the direction.
In plain wordsIn alcohol-preferring rats, MTII changed levels of two natural opioid peptides in several brain areas and the pituitary gland.
Peptide
Melanotan II
Outcome
Direction not reportedDynorphin B and Met-enkephalin-Arg(6)Phe(7) levels in brain areas and pituitary
Study
ratn: not reported in source
Alcohol-preferring AA rats
Comparator
Artificial cerebrospinal fluid
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1 nmol/rat · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
Analysis of dynorphin B and Met-enkephalin-Arg(6)Phe(7) immunoreactive levels revealed that MTII and HS014 altered opioid peptide levels in several brain areas and the pituitary gland of the rats with an established ethanol intake.
1 context sentence(design, population, supporting numbers)
Summary · context
To further study the involvement of the MCs in drug dependence, we analysed the effects of the MC(4)-receptor antagonist HS014 (1 nmol/rat), and the non-selective MC-receptor agonist MTII (1 nmol/rat), using i.c.v. administration, on ethanol intake in alcohol-preferring AA rats.
Report a problemFND-1237943905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.